The Thrive-131 study will evaluate the safety and efficacy of an investigational therapy called inclacumab to decrease vaso-occlusive crises in participants with sickle cell disease.
Over the course of 48 weeks, eligible participants will be given inclacumab or placebo, both through intravenous (IV) every 12 weeks to determine if this investigational drug therapy can improve the life of individuals living with sickle cell disease by decreasing the number of painful vaso-occlusive crises (VOCs).
This study is currently recruiting study participants in Atlanta, Georgia; Boston, Massachusetts; Ann Arbor, Michigan; Tripoli, Lebanon, Nini Hospital. If you live in other locations, please contact the study point of contact below to see if you can enroll in this study at a different time.
Supriya Rao | |
[email protected] |
3 USA sites
1 Lebanon site
12 years and older
All types of SCD
Clinical trial
All
Yes
A person CAN be eligible to participate in this study if they:
A person CANNOT be eligible to participate in this study if they: